Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 3 min ago
Peer-reviewedCC BYFrontiers in pharmacology

Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis

  • Samuel A. Fisch1
  • Eitan J. Neugut2
  • Nicole Cornet3
  • Daniela Quigee1
  • Alfred I. Neugut1
  • Daniel E. Freedberg1
  1. 1Department of Epidemiology, Mailman School of Public Health, Columbia University , , ,
  2. 2Department of Statistics, Columbia University , , ,
  3. 3Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University , , ,
Read full textPDFCite

Related

  1. Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review
    Aditya K. Gupta, Elizabeth M. Teasell, Renata F. Magalhães +2
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data
    Ethan J. Cannon, Wendy Wang, Faye L. Norby +5
    British Journal of Clinical PharmacologyPeer-reviewedCC BY 4.0Full text1 citedEndocrinology & metabolismPMC
  3. Musculoskeletal Adverse Event Signals Associated With Semaglutide, Liraglutide, and Tirzepatide in the US FDA Adverse Event Reporting System.
    Akshita Wadhwa, Dhruv Patel, Andrew Bouras +2
    CureusPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  4. Early postmarketing reporting patterns of resmetirom in FAERS: disproportionality analyses with indication-restricted and active comparators
    Xin Zhao, Bi Pan, Tianhao Chen +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  5. Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study
    Kazuki Nishida, Basile Chrétien, Charles Dolladille +6
    Clinical NutritionPeer-reviewedCC BY21 citedPharmacology & toxicologyHAL

Cite

BibTeXRIS
BibTeX
@article{fisch2026indicationspecific,
  title = {{Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis}},
  author = {Samuel A. Fisch and Eitan J. Neugut and Nicole Cornet and Daniela Quigee and Alfred I. Neugut and Daniel E. Freedberg},
  journal = {Frontiers in pharmacology},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13658941},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis
AU  - Samuel A. Fisch
AU  - Eitan J. Neugut
AU  - Nicole Cornet
AU  - Daniela Quigee
AU  - Alfred I. Neugut
AU  - Daniel E. Freedberg
PY  - 2026
DA  - 2026/10/16
JO  - Frontiers in pharmacology
UR  - https://europepmc.org/article/PMC/PMC13658941
SN  - 1663-9812
ER  -